RESTRUCTURING SUPPORT AGREEMENTRestructuring Support Agreement • October 31st, 2018 • Egalet Corp • Pharmaceutical preparations • New York
This RESTRUCTURING SUPPORT AGREEMENT (together with all exhibits, schedules and attachments hereto, as amended, supplemented or otherwise modified from time to time, this “Agreement”), dated as of October 30, 2018, is made and entered into by and among (1) Egalet Corporation (“Egalet”), a Delaware corporation, and its direct and indirect subsidiaries listed on the signature pages hereto (each, a “Company Party,” and collectively, the “Company”), and (2) the undersigned beneficial holders (or investment advisors or managers executing and delivering this Agreement for such beneficial holders) of Egalet Claims (as defined below) (together with their respective successors and permitted assigns, and any holder of Egalet Claims that becomes a party hereto in accordance with the terms hereof, each, a “Supporting Noteholder,” and collectively, the “Supporting Noteholders”).
TERMINATION AND SETTLEMENT AGREEMENTTermination and Settlement Agreement • October 31st, 2018 • Egalet Corp • Pharmaceutical preparations • New Jersey
THIS TERMINATION AND SETTLEMENT AGREEMENT (this “Agreement”) is dated as of October 29, 2018, by and between Halo Pharmaceutical, Inc., a Delaware corporation, having offices at 30 North Jefferson Road, Whippany, NJ 07981 (“Halo”), and Egalet Corporation, a Delaware corporation, having offices at 600 East Lee Road, Suite 100, Wayne, PA 19087, Egalet, Ltd, a UK company having offices at 160 Queen Victoria Street London EC4V 4QQ and Egalet US Inc., having offices at 600 Lee Road, Wayne, PA 19087 (collectively, “Client”). As used herein, Halo and Client are referred to collectively as the “Parties” and individually as a “Party”.
ASSET PURCHASE AGREEMENT by and between Iroko Pharmaceuticals Inc., Egalet US Inc., and Egalet Corporation Dated as of October 30, 2018Asset Purchase Agreement • October 31st, 2018 • Egalet Corp • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of October 30, 2018, by and between Iroko Pharmaceuticals Inc., a business company incorporated in the British Virgin Islands (registered number 1732699) (the “Company”) and Egalet US Inc., a Delaware corporation (“NewCo”), and Egalet Corporation, a Delaware corporation (“Buyer Parent” and, collectively with NewCo, the “Buyer”).
EMPLOYMENT SEPARATION AGREEMENT AND GENERAL RELEASEEmployment Separation Agreement and General Release • October 31st, 2018 • Egalet Corp • Pharmaceutical preparations • Pennsylvania
THIS EMPLOYMENT SEPARATION AGREEMENT AND GENERAL RELEASE (the “Agreement”) is entered into by and between Egalet Corporation, a Delaware Corporation (the “Company”), and Stanley J. Musial (“Executive” or “Musial”), effective following Executive’s signature of it without timely revocation (the “Effective Date”).
